New Zealand markets close in 5 hours 55 minutes
  • NZX 50

    11,721.19
    -7.31 (-0.06%)
     
  • NZD/USD

    0.6289
    +0.0049 (+0.78%)
     
  • ALL ORDS

    7,259.50
    +9.20 (+0.13%)
     
  • OIL

    90.46
    -0.30 (-0.33%)
     
  • GOLD

    1,804.70
    -0.50 (-0.03%)
     

Non-Alcoholic Steatohepatitis (NASH) Market Worth $24.26Bn, Globally, by 2028 at 47.1% CAGR - Exclusive Report by The Insight Partners

·10-min read
The Insight Partners
The Insight Partners

The non-alcoholic steatohepatitis (NASH) market size is projected to reach $24.26 billion by 2028 from $1.63 billion in 2021; it is expected to register a CAGR of 47.1% from 2021 to 2028.

New York, May 04, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Non-Alcoholic Steatohepatitis (NASH) Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib & Cenicriviroc, and Others), Application (Treatment and Diagnosis), and Sales Channel (Hospital Pharmacy, Online Provider, and Retail Pharmacy)”, the global non-alcoholic steatohepatitis (NASH) market growth is driven by the rising prevalence of NASH and increasing initiatives for the awareness of NASH, the growing number of clinical trials involving combination studies of drugs. However, the lack of established guidelines for the diagnosis and management of NASH, and withdrawal of drugs from the marketing authorization stage of clinical trials hamper the NASH market growth.


The Sample Pages Showcases Content Structure and Nature of Information Included in This Research Study Which Presents A Qualitative and Quantitative Analysis: https://www.theinsightpartners.com/sample/TIPRE00009653/


Report Coverage

Details

Market Size Value in

US$ 1.63 Billion in 2021

Market Size Value by

US$ 24.26 Billion by 2028

Growth rate

CAGR of 47.1% from 2021 to 2028.

Forecast Period

2021- 2028

Base Year

2021

No. of Pages

178

No. Tables

86

No. of Charts & Figures

77

Historical data available

Yes

Segments covered

Product, Application, and Sales Channel

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends


Non-Alcoholic Steatohepatitis (NASH) Market: Competitive Landscape and Key Developments
Genfit SA; One Way Liver, S.L.; BioPredictive S.A.S.; Cadila Pharmaceuticals Ltd.; Prometheus Laboratories; Siemens Healthineers AG; Intercept Pharmaceuticals, Inc.; Novartis AG; Galmed Pharmaceuticals; and Laboratory Corporation of America Holdings are among the leading companies in the non-alcoholic steatohepatitis (NASH) market. The market is anticipated to flourish with the development of innovative products in the coming years.

In November 2021, GENFIT announced that its NIS4 technology has been recognized in a Stage 1 study1 which is undertaken by the Non-Invasive Biomarkers of Metabolic Liver Disease (NIMBLE) initiative of the Foundation for the National Institutes of Health’s Biomarkers Consortium. This NIS4 technology demonstrated a unique performance in identifying patients with “at-risk” Non-Alcoholic Steatohepatitis (NASH).


Schedule A Pre-Sale Discussion with The Author Team in A Slot That You Prefer to Address Queries on Scope of The Study, Customization, Introduction to Research Methodology, Assistance on Technologies and Market Definitions: https://www.theinsightpartners.com/inquiry/TIPRE00009653/


In January 2022, Siemens Healthineers announced the launch of Enhanced Liver Fibrosis (ELF) Test in the US. This is the first time the test was made commercially available in the country, following the de novo marketing authorization from the US Food and Drug Administration (FDA) in August 2021.

North America holds the largest share of the non-alcoholic steatohepatitis (NASH) market, and the US accounts for the largest share of the regional market, followed by Canada and Mexico, respectively. The non-alcoholic steatohepatitis (NASH) market in the US is expected to grow rapidly with the growing cases of NASH and favorable government regulations encouraging the development of diagnostics procedures for this condition. On the International NASH Day on June 12, 2020, the American Liver Foundation joined a global community to raise awareness about NASH with support from the Allergan Foundation.

American Liver Foundation (ALF) is now piloting a NASH Text Messaging Program, wherein people can sign up to receive weekly 3 messages for 10 weeks. Messages consist of hyperlinks to NASH resources, NASH facts, interactive quizzes, and sensible pointers for everyday self-management. ALF will open this system to the general public when the pilot is finished and evaluated. It collaborated with the Global Liver Institute (GLI) on the International NASH Day 2020, and shared a few social media posts with links to GLI posts and the International NASH day page. Thus, rising initiatives for boosting awareness about NASH are driving the non-alcoholic steatohepatitis (NASH) market growth in North America.


Click Here to Avail Lucrative DISCOUNTS on Our Latest Research Reports. We Offer Student, Enterprise, and Special Periodic Discounts to Our Clientele. Please Fill the Form to Know DISCOUNTED PRICE


According to the data provided by the National Center for Biotechnology Information (NCBI), the number of prevalent NASH cases would increase by 35% in Canada from 2019 to 2030, to reach 2,630,000. Among the total non-alcoholic fatty liver disease (NAFLD) population, 25.2% of cases had NASH in 2019,which is expected to increase to 28.3% in 2030. In 2019, the all-age prevalence of NASH increased from 5.2% (4.2%–6.2%) to 6.5% (5.2%–7.7%) on average, and the age-adjusted prevalence would increase from 5.2% (4.2%–6.2%) to 6.1% (4.9%–7.2%) on average. Of NASH cases in 2019, stage F3–F4 fibrosis, decompensated cirrhosis, hepatocellular carcinoma or liver transplantation accounted for 349,000 cases, encompassing 17% of estimated NASH cases and 0.9% of the Canadian population (all ages). This increase in cases with extreme conditions in NASH is fueling the growth of Canada NASH market. By 2030, this number is expected to increase by 65% to reach 578 000 cases, and account for 1.0% of the total population, including 22% of predicted NASH cases. This estimated increase in the cases of NASH is fueling the growth of the non-alcoholic steatohepatitis market in Canada.

Rising Prevalence of NASH Fuels Market Growth:
NASH is a potentially fatal illness that causes extensive scarring and cirrhosis of the liver. NAFLD is the most common chronic liver disease globally. NASH is a progressive form of NAFLD, which is gradually becoming the major cause of end-stage liver diseases and liver transplantation. According to the data published by the Global Liver Institute, NASH was termed as an epidemic on June 12, 2019. It affects over ~115 million people, and 357 million people are expected to be affected by this condition by 2030. Obesity, type 2 diabetes, and hyperlipidemia are substantial risk factors for NAFLD and NASH; more than ~70% of people are obese, ~75% have type 2 diabetes, and 20–80% have hyperlipidemia worldwide. NASH, if left untreated, can progress to cirrhosis and liver cancer, and raise the need for a liver transplant.


Have A 15-Minute-Long Discussion with The Lead Research Analyst and Author of The Report in A Time Slot Decided by You. You Will Be Briefed About the Contents of The Report and Queries Regarding the Scope of The Document Will Be Addressed as Well: https://www.theinsightpartners.com/speak-to-analyst/TIPRE00009653


As per the data published by the American Liver Foundation, NAFLD is the most common chronic liver disease in the US. ~25% of adults in the US have been estimated to have NAFLD, of which ~20% have NASH, i.e., 5% of adults in the US. According to the NASH Education Program, NASH prevalence is expected to increase by 63% from 2015 to 2030 and NASH is predicted to become the major cause of liver transplantation in the US during 2020–2025. The American Association for the Study of Liver Diseases published a report in 2018 using Markov modeling to forecast NAFLD disease till 2030. As per the study, the prevalence of NAFLD and NASH cases is expected to increase by 21% and 63%, respectively, resulting in 33.5% and 27% prevalence rates, respectively, in adults.

Despite its increasing prevalence, NAFLD/NASH remains an under-recognized condition, and early detection is critical to reducing the risk of progression and its associated consequences. Thus, the growing prevalence of NASH drives the non-alcoholic steatohepatitis (NASH) market.


Non-Alcoholic Steatohepatitis (NASH) Market: Segmental Overview

Product-Based Insights:
The non-alcoholic steatohepatitis (NASH) market, by product, is segmented into vitamin E and pioglitazone, ocaliva, elafibranor, selonsertib & cenicriviroc, and others. In 2021, the others segment held the largest share of the market. The selonsertib & cenicriviroc segment is expected to register the fastest CAGR in the non-alcoholic steatohepatitis (NASH) market from 2021 to 2028.

Application-Based Insights:
The non-alcoholic steatohepatitis (NASH) market, based on application, is segmented into treatment and diagnosis. In 2021, the treatment segment held a larger share of the market. However, the treatment segment is expected to register a higher CAGR during the forecast period.


Immediate Delivery of Our Off-The-Shelf Reports and Latest Research Studies, Through Flexible and Convenient Payment Methods: https://www.theinsightpartners.com/buy/TIPRE00009653/


Sales Channel-Based Insights:
The non-alcoholic steatohepatitis (NASH) market, based on distribution channel, is segmented into hospital pharmacy, retail pharmacy, and online provider. In 2021, the retail pharmacies segment held the largest share of the market. Moreover, it is expected to register the highest CAGR in the non-alcoholic steatohepatitis (NASH) market during 2021–2028.




Browse Adjoining Reports:
Non-alcoholic Steatohepatitis Biomarkers Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Serum biomarkers, Hepatic fibrosis biomarkers, Apoptosis biomarkers, Oxidative stress biomarkers, Others); Application (Pharmaceutical and CRO Industry, Hospitals, Diagnostic Labs, Academic Research Institutes) and Geography

Antidiabetic Thiazolidinediones Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Rosiglitazone, Pioglitazone); End User (Hospital, Clinic, Others ), and Geography

Liver Cancer Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Laboratory Tests, Endoscopy, Imaging, Biopsy, and Others) and End User (Hospitals and Diagnostic Laboratories, Academic and Research Institutes, and CRO Laboratories)

Human Liver Models Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Liver Organoids, Liver-on-a-Chip, 2D Models, 3D Bioprinting, and Others), Application (Drug Discovery, Educational, and Other), and End User (Pharmaceutical and Biotechnology Companies, Research Institutes, and Others)

Liver Diseases Treatment Market to 2025 - Global Analysis and Forecasts by Diseases (Cirrhosis, Hepatitis, Cancer and Other Diseases), Imaging Modality (Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Ultrasound, and Other Modalities) and Geography

Liver Medicine Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Treatment Modality (Anti-viral, Vaccines, Chemotherapy, Immunosuppressive Agents, Corticosteroids); Disease Type (Hepatitis, Non- alcoholic fatty liver disease, Alcohol-induced liver disease, Liver Cancer); End-user (Hospitals, Specialty Clinics, Others) and Geography

Liver Detox Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Type (Tablets, Capsules, Liquid and Sprays, Others); Application (Hospitals, Individuals, Institutions, Others)

Liver Cirrhosis Therapeutics Drugs Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Hepatitis C-related Cirrhosis, Alcoholic Cirrhosis, Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis, Others); Stage type (Compensated cirrhosis, Decompensated cirrhosis); Drug Type (Ursodeoxycholic acid, Obeticholic acid, Azathioprine, Colchicine, Others); Route of Administration (Oral, Intravenous, Others); End User (Hospitals, Homecare, Specialty Clinics, Others) and Geography

Hepatitis Diagnostic Tests Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Instruments, Kits and reagents, Point of care tests); Test Type (Blood tests, Imaging tests, Liver biopsy) End User (Hospitals, Diagnostic Laboratories, Blood Banks, Others) and Geography





About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:
If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876
Press Release: https://www.theinsightpartners.com/pr/non-alcoholic-steatohepatitis-nash-market


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting